ADVERTISEMENTFor India, the immediate impact of the pharma tariff appears to be limited. Around 90 per cent of India’s pharmaceutical exports to the US are generics (off patented), which continues to remain exempt. Under the updated rules, the existing 50 per cent tariff on primary metals will now be calculated based on US purchase prices rather than declared export values. While sparing generics provides relief to India, firms producing branded or speciality drugs, or supplying inputs for patented medicines, could face tariff pressure, the Global Trade Research Initiative (GTRI) observed. The 100 per cent tariffs will mainly affect Ireland, Germany, Switzerland, Belgium, Denmark, the United Kingdom and Japan, which are major exporters of patented and high-value drugs, including biologics, to the US.

Source: The Telegraph April 04, 2026 10:16 UTC